|
**Overview**: Hemophilia A Carrier Panel**Introduction**: The Hemophilia A Carrier Panel is a diagnostic tool designed to detect hemophilia A carrier status using whole blood samples. In India, hemophilia A (F8 gene mutations) affects ~1 in 5,000â€"10,000 males, with carriers (~50 percent daughters of affected males) at risk of transmitting severe disease or having mild bleeding symptoms. High morbidity from under-testing in rural/low-SES families with bleeding history, limited genetic labs, delayed prenatal diagnosis or counseling leading to affected births. Per molecular pathology practices aligned with ICMR and Indian Society of Hematology guidelines, the test employs PCR for F8 gene mutations and intron 22 inversion over 1-2 days with high accuracy, valuable for carrier detection and family planning. This diagnostic falls under genetic disorder screening and targets female relatives of hemophilia patients or women with bleeding symptoms, addressing accurate detection to guide genetic counseling and prenatal testing. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise carrier identification and reducing hemophilia burden. Its whole blood-based approach ensures reliable mutation detection.**Other Names**: Hemophilia A Pnl.**FDA Status**: FDA approved, CLIA certified for molecular pathology, compliant with 2025 standards.**Historical Milestone**: F8 carrier testing standard; in India, used in hemophilia centers.**Purpose**: The test assesses 3 parameters including F8 gene mutation to guide hemophilia A carrier screening, detect mutations/inversions, inform counseling.**Test Parameters**: 1. F8 Gene Mutation, 2. Intron 22 Inversion, 3. Carrier Status.**Pretest Condition**: No fasting required; patients should have family history of hemophilia.**Specimen**: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for PCR).**Medical History**: Patients should provide details on family bleeding history, personal bleeding symptoms.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of carrier status including transmission to sons, benefits of detection, and minimal discomfort from blood draw.**Procedural Considerations**: The test involves sample processing using PCR by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low DNA yield can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive mutation/inversion confirms carrier status, necessitating specialist input.**Specialist Consultation**: Hematologists or geneticists should be consulted for management.**Additional Supporting Tests**: Factor VIII assay, linkage analysis for confirmation.**Test Limitations**: Detects common mutations; comprehensive approach required.**References**: Indian Journal of Hematology 2024, Hemophilia Studies India 2023. |
